{‘She has zero expertise’: the US healthcare field prepares for Høeg's appointment at the FDA.

Given that the US undertakes sweeping changes to its vaccine guidelines, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations during the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Schedule

Agency leaders planned to announce radical revisions to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US at odds with much of the global community with no evidence for benefit. The planned update has been delayed until the coming year.

In place of Vinay Prasad, Høeg is scheduled to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the drug and biologics branches as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a country with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Background

The appointee has no apparent track record in medication creation, approval processes or management, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Former commissioners of CBER would “grasp laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who led CBER have had.”

The drug center has an immense range of responsibilities at the agency, she emphasized.

“The public just zeroes in on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be looked after,” she explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant administrative component to the position, which manages in excess of 5,000 employees. “It is a huge administrative position, if you do it right,” the former official added.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Høeg’s qualifications and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a representative responded that the “concerns rely on inaccurate premises”.

“This background is consistent with the functions of her position,” the official said, pointing to the months Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid therapy clearance system that apparently worried her predecessors. “How are these therapies being chosen for this voucher program? Who takes the choices?” Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards laxer rules of all drugs, with the exception of immunizations.”

Public Past Work on Vaccines

With immunizations, Dr. Høeg has a clearer, if troubling, track record, Howard observe. She released a analysis using unverified public submissions to determine the rate of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming government featured revising guidelines for new vaccines and discontinuing “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has reportedly suggested barring teenage boys from receiving Covid vaccinations.

“She is an thorough ideologue who starts off with her conclusions and works backwards to fit the science in a very disingenuous, dishonest way,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|